E-64

Modify Date: 2024-01-06 20:58:58

E-64 Structure
E-64 structure
Common Name E-64
CAS Number 66701-25-5 Molecular Weight 357.405
Density 1.4±0.1 g/cm3 Boiling Point N/A
Molecular Formula C15H27N5O5 Melting Point 182ºC
MSDS Chinese USA Flash Point N/A
Symbol GHS08
GHS08
Signal Word Warning

 Use of E-64


E-64 is a potent irreversible inhibitor against general cysteine proteases with IC50 of 9 nM for papain.

 Names

Name e64
Synonym More Synonyms

 E-64 Biological Activity

Description E-64 is a potent irreversible inhibitor against general cysteine proteases with IC50 of 9 nM for papain.
Related Catalog
Target

IC50: 9 nM (Papain)[1]

In Vitro E-64 is a cathepsin B-specific inhibitor, and its binding modes with papain, actinidin, cathepsin L, and cathepsin K have been reviewed at the atomic level. E-64 has been widely used as a potent and irreversible (covalent-type) inhibitor for many cysteine proteases such as papain, ficin, actinidin, cathepsin B and L[1]. The S.cervi adult parasites are incubated in the Kreb's Ringer bicarbonate (KRB) maintenance medium for 8 h at 37°C, 5% CO2 with 5, 10, 20 and 40 μM concentration of E-64. E-64 shows a concentration and time dependent decrease in motility and viability of the parasites (EC50=16 μM)[2].
In Vivo A broad spectrum of expression of CD4 and CD19 is found exists in both the islets and pancreatic lymph nodes (PLNs) and that anti-serpin B13 mAb exposure causes a significant shift that favored cells expressing low-to-intermediate amounts of these markers. However, this shift is abolished in animals that receive anti-serpin B13 mAb in the presence of the protease inhibitor E-64 (E64), which maintains its blocking activity under the experimental conditions used[3]. Dahl salt-sensitive (SS) rats are fed an 8% high salt NaCl diet and intravenously infused with the irreversible cysteine cathepsin inhibitor E-64 (1 mg/day) or the vehicle (control). Both the control and E-64 infused groups develope significant hypertension and kidney damage, and no difference of the mean arterial pressure and the hypertension-associated albuminuria is observed between the groups[4].
Kinase Assay The Cathepsin B activity is determined using Z-Arg-Arg-4mβNA as substrate with slight modifications. The crude extract is pre-incubated at 37°C for 5 min in 50 mM sodium acetate buffer, pH 5.0 containing 1 mM EDTA and 5 mM DTT. The substrate (final concentration, 100 μM) is added to make the final assay volume of 1 mL. The reaction mixture is incubated at 37°C for 30 min. The reaction is terminated by adding equal volume of stopping reagent containing Fast Garnet GBC salt (1 mg/mL), 10 mM pHMB and 50 mM EDTA, pH 6.0. The extraction of product, β-napthylamine (β-NA), is carried out with n-butanol. After complete layer separation, the absorbance is measured in n-butanol layer and activity is calculated using molar extinction coefficient of β-napthylamine solution as 31.5 M/cm per sec at 520 nm. One unit of enzyme activity is defined as the amount of enzyme liberating 1 μmol of βNA per minute at 37°C. The half maximal inhibitory concentration (IC50) is calculated by plotting the graph between the different concentration of E-64 and the % inhibition in cathepsin B activity. Here, IC50 indicates the concentration of the E-64 required to inhibit the parasitic cathepsin B activity by half[2].
Animal Admin Mice[3] The NOD/LtJ and BDC2.5 T cell receptor (TCR) transgenic NOD mice are used to study the effects of treatment with anti-serpin B13 monoclonal antibody (mAb). Four-week-old female NOD/LtJ mice are injected intravenously four times over a period of 10 days with anti-serpin B13 mAb (100 μg/injection). In addition, during the same period, some animals are also injected intraperitoneally with the protease inhibitor E64 at 10 mg/kg/day for several days. Control mice are treated with diluent (a sterilized PBS solution containing 10% DMSO) and control IgG. The solutions containing E64 or DMSO are prepared immediately before use. Twenty-four hours after the last injection, the mice are killed, and cells from their lymphoid organs and pancreatic islets are subjected to FACS analysis. Rats[4] Seven-week old male Dahl Salt Sensitive rats (SS/JrHsdMcwi) are used. Briefly, 8-week old anesthetized SS rats have their left femoral artery and vein catheterized. Both catheters are fixed and exteriorized from the back of the neck and the arterial line is connected to a heparinized saline infusion pump that is in line with a blood pressure transducer, and the venous line is connected to a saline infusion pump. Animals are allowed 360° movement using a tether-swivel system. This preparation allowed chronic venous infusion and arterial blood pressure measurement in conscious, freely moving rats. A stable baseline blood pressure is obtained for 4 days prior to switching both groups to an 8.0% NaCl diet and the simultaneous addition of E-64 (1 mg/day; 280 mM stock in DMSO) or the vehicle (DMSO in saline) control to the venous catheter. Daily MAP is calculated by averaging MAP taken every min over the beginning 3 h period of the rat sleep cycle.
References

[1]. Matsumoto K, et al. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives. Biopolymers. 1999;51(1):99-107.

[2]. Wadhawan M, et al. Inhibition of cathepsin B by E-64 induces oxidative stress and apoptosis in filarial parasite. PLoS One. 2014 Mar 25;9(3):e93161.

[3]. Baldzizhar R, et al. Anti-serpin antibody-mediated regulation of proteases in autoimmune diabetes. J Biol Chem. 2013 Jan 18;288(3):1612-9.

[4]. Blass G, et al. Chronic cathepsin inhibition by E-64 in Dahl salt-sensitive rats. Physiol Rep. 2016 Sep;4(17). pii: e12950.

 Chemical & Physical Properties

Density 1.4±0.1 g/cm3
Melting Point 182ºC
Molecular Formula C15H27N5O5
Molecular Weight 357.405
Exact Mass 357.201233
PSA 169.93000
LogP -1.46
Index of Refraction 1.618
Storage condition 2-8°C
Water Solubility H2O: 20 mg/mL, clear, colorless

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
RR0390000
CHEMICAL NAME :
Oxiranecarboxylic acid, 3-(((1-(((4-((aminoiminomethyl)amino)butyl)amino)carb onyl)-3-methyl butyl)amino)carbonyl)-, (2S-(2-alpha,3-beta(R*)))-
CAS REGISTRY NUMBER :
66701-25-5
BEILSTEIN REFERENCE NO. :
1405664
LAST UPDATED :
199806
DATA ITEMS CITED :
3
MOLECULAR FORMULA :
C15-H27-N5-O5
MOLECULAR WEIGHT :
357.47

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
60 mg/kg
SEX/DURATION :
female 9-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
APDJBE Acta Paediatrica Japonica (Overseas Edition). (Societas Pediatrica Japonica, 1-1-5-Koraku, Bunkyo-ku, Tokyo, 112, Japan) V.1- 1958- Volume(issue)/page/year: 32,495,1990
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
60 mg/kg
SEX/DURATION :
female 9-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - urogenital system
REFERENCE :
APDJBE Acta Paediatrica Japonica (Overseas Edition). (Societas Pediatrica Japonica, 1-1-5-Koraku, Bunkyo-ku, Tokyo, 112, Japan) V.1- 1958- Volume(issue)/page/year: 32,495,1990
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
50 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
KDIZAA Kagoshima Daigaku Igaku Zasshi. Medical Journal of Kagoshima University. (Kagoshima Daigaku Igakkai, 1208-1, Usuki-cho, Kagoshima 890, Japan) V.1- 1945- Volume(issue)/page/year: 48,1,1996

 Safety Information

Symbol GHS08
GHS08
Signal Word Warning
Hazard Statements H371
Precautionary Statements P260-P264-P270-P308 + P311-P501
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes T+
Risk Phrases R68/20/22
Safety Phrases S22-S24/25
RIDADR NONH for all modes of transport
WGK Germany 3
RTECS RR0390000

 Articles115

More Articles
Low concentrations of Bisphenol A and para-Nonylphenol affect extravillous pathway of human trophoblast cells.

Mol. Cell. Endocrinol. 412 , 56-64, (2015)

Bisphenol A (BPA) and para-Nonylphenol (p-NP) are chemicals of industrial origin which may influence human reproductive health. The effects of these substances in the prenatal life is an important top...

The role of matrix metalloproteinases and cysteine-cathepsins on the progression of dentine erosion.

Arch. Oral Biol. 60 , 1340-5, (2015)

To evaluate in vitro the effect of the inhibition of endogenous dentinal enzymes (matrix metalloproteinases-MMPs and cysteine cathepsins-CCs) on dentine erosion.Dentine blocks (4mm×4mm×2mm) from sound...

Indomethacin inhibits activation of endothelial nitric oxide synthase in the rat kidney: possible role of this effect in the pathogenesis of indomethacin-induced renal damage.

Chem. Biol. Interact. 221 , 77-87, (2014)

The clinical use of non-steroidal anti-inflammatory drugs (NSAIDs) is often associated with adverse effects in the kidney. Indomethacin, an NSAID that has been shown to induce oxidative stress in the ...

 Synonyms

E64
proteinaseinhibitore64
thiolproteaseinhibitor
(L-3-trans-carboxyoxiran-2-carbonyl)-L-leucyl-agmatin
L-TRANS-EPOXYSUCCINYL-LEU-4-GUANIDINOBUTYLAMIDE
E-64
(2S,3S)-3-({(2S)-1-[(4-Carbamimidamidobutyl)amino]-4-methyl-1-oxopentan-2-yl}carbamoyl)oxirane-2-carboxylic acid
E-64 PROTEASE INHIBITOR
E-64 HEMIHYDRATE
e64(proteinaseinhibitor)
E-64,L-trans-Epoxysuccinyl-Leu-agMatine
L-TRANS-EPOXYSUCCINYL-LEU-AGMATINE
EPOXYSUCCINYL-L-LEUCYLAMIDO-(4-GUANIDINO)BUTANE
2-Oxiranecarboxylic acid, 3-[[[(1S)-1-[[[4-[(aminoiminomethyl)amino]butyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-, (2S,3S)-
MFCD07366493
(2S,3S)-3-({(2S)-1-[(4-Carbamimidamidobutyl)amino]-4-methyl-1-oxo-2-pentanyl}carbamoyl)-2-oxiranecarboxylic acid